Century Therapeutics reports Phase 1 ELiPSE-1 data: 30% CRR, 40% ORR in R/R NHL; no DLTs

Century Therapeutics, Inc.

As of March 27, 2024, 12 patients evaluable for safety; no DLTs or GvHD observed; most cycles outpatient.
Across all dose levels (10 evaluable), 30% complete response rate and 40% objective response rate.
At Schedule A dose levels 300M and 1B cells, 40% CRR and 60% ORR in 5 heavily pre-treated patients.
Novel cfDNA assay suggests CNTY-101 persists in tissues; AUC trends with dose.
Dose escalation continues at DL3B (3 weekly infusions of 1B cells) and DL4A (single 3B cells).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.